ArticleCancer research communications2024

Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.

Alana L Keller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.